Drugs
Công bố khoa học tiêu biểu
* Dữ liệu chỉ mang tính chất tham khảo
Sắp xếp:
The Role of Lipid-Lowering Therapy in Multiple Risk Factor Management
Drugs - Tập 56 - Trang 1-7 - 2012
Epidemiological studies have demonstrated that the risk of death from coronary heart disease (CHD) increases in parallel with increasing serum cholesterol levels. The risk is highest in patients with severely elevated cholesterol levels [i.e. >6.2 mmol/L (240 mg/dl)]. However, even in patients with serum cholesterol levels of 4.7 to 5.7 mmol/L (180 to 220 mg/dl), mortality from CHD is 30 to 70% hi......
Semaglutide: First Global Approval
Drugs - Tập 78 - Trang 275-284 - 2018
Novo Nordisk has developed a subcutaneous formulation of semaglutide (Ozempic®), a modified human glucagon-like peptide-1 (GLP-1) analogue, for the treatment of type 2 diabetes mellitus. It has been developed using Novo Nordisk’s proprietary protein-acylation technology, and is administered using an injection device. Semaglutide lowers blood glucose by stimulating the release of insulin and also l......
Azithromycin
Drugs - Tập 51 - Trang 483-505 - 2012
The azalide antibacterial agent azithromycin is a semisynthetic acid-stable erythromycin derivative with an expanded spectrum of activity and improved tissue pharmacokinetic characteristics relative to erythromycin. The drug is noted for its activity against some Gram-negative organisms associated with respiratory tract infections, particularly Haemophilus influenzae. Azithromyc......
Etretinate
Drugs - Tập 26 - Trang 9-43 - 2012
Synopsis: Etretinate1 (Ro 10-9359) is a new aromatic retinoic acid derivative for the treatment of severe psoriasis and other dyskeratoses. The pharmacological profile of etretinate suggests that it acts by normalising pathological changes in epidermal and dermal skin, particularly inhibiting hyperkeratinisation and cell differentiation, although its specific mode of action in dif......
Activity of Moxifloxacin Against Moraxella catarrhalis and Atypicals
Drugs - Tập 58 - Trang 344-345 - 2012
Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation
Drugs - Tập 81 - Trang 849-856 - 2021
Encorafenib (Braftovi®) is an oral small molecule BRAF inhibitor used in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, who have received prior systemic therapy. In a clinical trial in adults with BRAF V600E-mutated mCRC who had disease progression after one or two previous regimens (BEACON CRC), encorafenib plus ......
Guidelines for the Use of Propafenone in Treating Supraventricular Arrhythmias
Drugs - Tập 50 - Trang 250-262 - 2012
Propafenone is a sodium channel blocking agent with a mild β- and calcium channel-blocking activity. Several controlled and noncomparative studies have documented its efficacy in a variety of supraventricular arrhythmias in both adults and children. Propafenone is comparable with other Vaughan-William class I antiarrhythmic drugs for acute conversion of atrial fibrillation. It is also comparable w......
Recent Antiplatelet Drug Trials in the Acute Coronary Syndromes
Drugs - Tập 56 - Trang 965-976 - 2012
This paper reviews the results of 4 recent clinical trials, Platelet Receptor inhibition for Ischaemic Syndrome Management (PRISM), Platelet Receptor inhibition for Ischaemic Syndrome Management in Patients Limited to very Unstable Signs and symptoms (PRISM-PLUS), Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organisation Network (PARAGON A), and Plat......
Cefotaxime A review of its Antibacterial Activity, Pharmacological Properties and Therapeutic Use
Drugs - Tập 25 Số 3 - Trang 223-289 - 1983
Tổng số: 6,255
- 1
- 2
- 3
- 4
- 5
- 6
- 10